media – Page 15 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

1.8 billion, the integration of two major pharmaceutical companies of “China Resources”

On November 21, China Resources Pharmaceutical issued the “Latest Information on the Proposed Internal Restructuring of its China Resources Shenghuo” announcement. China Resources Sanjiu and Kunming Pharmaceutical Group have entered into an equity transfer agreement. China Resources Sanjiu has conditionally agreed to sell, and Kunming Pharmaceutical Group has conditionally agreed to acquire 51% of the equity of China Resources Shenghuo, with a total price of 1.791 billion yuan (equivalent to approximately HK$1.938 billion). It is expected that China Resources Sanjiu will use the funds to supplement operating funds. After the internal restructuring is completed, China Resources Pharmaceutical’s interest in China Resources Shenghuo will be reduced from approximately 63.02% to 39.90%, and China Resources Shenghuo will remain a non-wholly owned subsidiary of China Resources Pharmaceutical. On the same day, China Resources Sanjiu announced that it had signed the “Equity Transfer Agreement between China Resources Sanjiu Pharmaceutical Co., Ltd. and Kunming Pharmaceutical ...
- Source: drugdu
- 53
- November 28, 2024
Huadong Medicine’s “GLP-1R/GCGR/FGF21R triple agonist” was approved for new clinical trials

On November 15, according to the official website of CDE, the Class 1 new drug DR10624 injection of Huadong Medicine’s subsidiary Daoer Biotechnology has obtained implicit approval for clinical trials, and its indications are metabolic-related fatty liver disease/metabolic-related fatty hepatitis. According to public information, the drug is a GLP-1R/GCGR/FGF21R triple agonist. DR10624 is a chimeric peptide segment targeting GLP1R/GCGR at the N-terminus, fused to an engineered IgG1 Fc, and a recombinant FGF21 mutant is fused to the C-terminus of the Fc. Preclinical study results show that DR10624 has strong metabolic regulation and improved efficacy. Huadong Medicine mentioned in the announcement that DR10624 is a symmetrical dimer in structure. While having the biological activity of GLP-1R, GCGR, and FGF21R triple agonists, it can also be fused with a deglycosylated IgG1 Fc to extend the half-life. In April 2022, Doer Biopharma was approved to conduct a Phase I clinical trial of DR10624 ...
- Source: drugdu
- 62
- November 28, 2024
“Innovative Cardiac Tissue Ablation Clip” approved by CE

AtriCure, a leading company in the treatment of atrial fibrillation, announced today that its EnCompass cardiac tissue ablation clip has received the EU CE mark, meaning the device can be sold in more than 30 countries in the European Economic Area (EEA). A number of innovative products were launched AtriCure was founded in 2000 and focuses on cardiac surgery solutions. The company mainly produces and sells cardiac ablation devices, providing innovative technologies for the treatment of atrial fibrillation and related diseases. At present, AtriCure has 138 authorized patents in the United States and has served more than 300,000 patients with atrial fibrillation since 2004. It is understood that the EnCompass cardiac tissue ablation clamp is used for cardiac tissue ablation surgery, including comprehensive epicardial ablation of the left atrium during open heart surgery. This is a simpler and faster method of open-chest cardiac ablation, allowing doctors to perform comprehensive epicardial ...
- Source: drugdu
- 55
- November 28, 2024
HOSPITALAR

Organiser：Informa Markets Time：May 20th – 23rd, 2025 Address： Centro de Exposições Imigrantes, Rodovia dos Imigrantes, Km 1.5, São Paulo – SP Exhibition hall：São Paulo Expo Product range: Medical Equipment Exhibition Area: Hospital technology facilities and equipment; medical clinic technology and equipment; ward furniture and equipment; diagnostic and treatment equipment; biochemical and testing equipment; pharmaceutical products; hygienic materials; medical communication technology and equipment; comprehensive hospital information technology and services. Rehabilitation Technology for Disabled Exhibition Area: Nursing equipment; nursing products; communication technology; mobile nursing; nursing services; medical technology; orthopedic technology; outpatient nursing; physiotherapy; prosthetics; services; ergotherapy; communication technology; wheelchairs. Pharmaceutical Exhibition Area: Prescription drugs; traditional Chinese medicines; western medicines; antibiotics; powdered injections; infusions; tablets; ointments; capsules; various new drugs; specialty drugs; national protected traditional Chinese medicine varieties; national basic medical insurance drugs; pharmaceutical raw materials; various intermediates; biochemical reagents and vaccines; various biological products. Dental Exhibition Area: Dental instruments and equipment; dental ...
- Source: drugdu
- 80
- November 28, 2024
Strategic layout of biopharmaceutical new track, construction of latecomer new advantages

A person in charge of Northeast Pharmaceutical recently stated in an interview with China Securities Journal that in recent years, the company has strategically laid out a new track for biopharmaceuticals and seized the pharmaceutical “blue ocean” market with more “new brand” products. In the future development, the company will continue to implement the “innovation+imitation” dual wheel drive strategy, and on the basis of further strengthening traditional businesses such as raw materials and chemical generic drugs, continue to focus on the new track of biopharmaceuticals, fully build new advantages for latecomers, and provide strong impetus for long-term development. Entering the field of cell therapy As an old pharmaceutical company with a history of 78 years, Northeast Pharmaceutical has always focused on raw materials and chemical generic drugs as its main products. It should be noted that in the pharmaceutical industry, including sub sectors such as chemical drugs, the track is ...
- Source: drugdu
- 62
- November 27, 2024
【EXPERT Q&A】How does the medical device industry develop new channels and new markets under the normalization of collective mining?

Drugdu.com expert’s response: In the context of normalized centralized procurement, the medical device industry faces a new market environment and competitive landscape. To explore new channels and markets, enterprises can proceed from the following aspects: Ⅰ. Optimize Resource Allocation to Enhance Product Competitiveness Focus on Innovative Research and Development: Medical device enterprises should increase investment in innovative research and development to launch products with differentiated competitive advantages, thereby avoiding the risks associated with centralized procurement of homogeneous products. Through innovation, enterprises can open up new market segments, meet the needs of specific patients, and thus obtain higher market shares and profit margins. Diversify Product Lines: Expand the industry chain and enhance risk resistance capabilities with a multi-product portfolio. Enterprises can achieve seamless integration of the industry chain by acquiring upstream and downstream related enterprises, thereby enhancing product competitiveness and creating a synergistic effect. Ⅱ. Leverage Centralized Procurement Platforms to Expand Sales ...
- Source: drugdu
- 83
- November 27, 2024
Schott Pharmaceuticals, Corplex, and Takeda Pharmaceuticals successfully demonstrate closed-loop recycling systems

Together with Takeda Pharmaceuticals and Corplex, Schott Pharmaceuticals has successfully conducted a ton level emission reduction pilot study, improving resource utilization efficiency and reducing carbon emissions in the pharmaceutical supply chain Research has shown that closed-loop recycling of pallets used for packaging and shipping drug sealing solutions is technically and supply chain feasible. When using 70% recycled materials for pallets, greenhouse gas (GHG) emissions can be reduced by up to 50%. Schott Pharmaceuticals, a supplier of drug packaging and delivery solutions, Corplex, a leader in transportation packaging design, manufacturing, and recycling, and Takeda Pharmaceuticals, a leading global biopharmaceutical company, are collaborating to promote circular economy solutions in the pharmaceutical industry. Three companies have collaborated to conduct a pilot study on the closed-loop recycling of disposable pallets. During drug transportation, these trays are used to hold injection bottles, syringes, and ampoules, and are currently only for disposable use. We strive to ...
- Source: drugdu
- 56
- November 27, 2024
The world’s first self shielding radiotherapy robot will be mass-produced on a large scale in China

As one of the important treatment methods for tumors, the global radiotherapy industry is currently entering the path of precision, intelligence, and personalized development. Among them, precision radiotherapy, as an efficient, personalized, and precise cancer treatment method, is considered a new era in cancer treatment. Recently, there has been good news from the radiation therapy industry once again. On November 25th, Baiyang Pharmaceutical officially announced the acquisition of ZAP Surgical Systems, Inc.’s head and neck X-ray radiosurgery treatment system (trade name: ZAP-X) ® The exclusive commercial rights of the Mars Ark Radiosurgical Robot (ZAP-X) and related accessories in mainland China, Hong Kong, and Macau will fully promote the faster landing and wider application of ZAP-X in the Chinese market. 01. The world’s first self shielded radiotherapy surgical robot, solving pain points in the head and neck radiation surgery industry Public information shows that the common indications for ZAP-X include all ...
- Source: drugdu
- 54
- November 27, 2024
Rushing towards NASDAQ, another Chinese new drug company has arrived

In June 2023, Astellas Pharma Inc. announced a research collaboration and exclusive selection agreement with Cullgen for a total amount of up to $1.9 billion, with a $35 million advance payment and $85 million option exercise fee. Used for collaborative development of potential first in class protein degrading agents. On November 13, 2024, Pulmatrix (NASDAQ: PULM) announced a merger agreement with Cullgen. At present, Cullgen has three degradation agent projects that are about to or are in the process of initiating phase I clinical trials. Two of the projects are used to treat cancer, and one project is used to treat acute and chronic pain. The merged company is expected to have approximately $65 million in cash and cash equivalents upon completion of the merger, providing funding for multiple clinical milestones and expected to sustain operations until 2026. CG001419 is an oral pan TRK degrader in the clinical stage, and ...
- Source: drugdu
- 68
- November 27, 2024
MNC applauded, Biotech loosened up

On November 6, Trump scored twice and won the new US presidential election. The White House once again welcomed this Republican familiar. For a long time, the Republican Party has been more conservative and “cold” towards the biopharmaceutical industry than the Democratic Party. Trump is no exception: the Republican Party takes the “small government” route, and he has long focused his position on opposing government intervention. For pharmaceutical companies, this is a good thing: a relatively loose policy environment is more conducive to the free development of the industry. A pharmaceutical practitioner in the United States explained the industry sentiment in this way: “Generally speaking, Pharma believes that Trump may revise the previous radical IRA (Inflation Reduction Act) and re-emphasize market logic; some biotechs are on the sidelines; the worst may be some public research institutions and public health institutions. According to Trump’s previous attitude, their funding will be much ...
- Source: drugdu
- 65
- November 27, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.